Showing results (381-390 of 824) with videos related to
Sort By:
Pageof 83
Clinical Advances in Hematology & Oncology : H&O|August 28, 2018
The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous diseaseSara Gandolfi, Carolyn Vekstein, Jacob P Laubach, et al.Cancer Research|May 17, 2003
Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusionEnrica Orsini, Roberto Bellucci, Edwin P Alyea, et al.JACC. Advances|October 28, 2025
Prevalence of Sleep Apnea and Echocardiographic Correlates in a Community-Based Cohort of Cardio-Oncology PatientsMini K Das, John L Huber, Jamie D Kemp, et al.Cancer Research|September 6, 2005
Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cellsMikael Altun, Paul J Galardy, Reshma Shringarpure, et al.Expert Opinion on Drug Safety|October 31, 2023
A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myelomaShonali Midha, Monique A Hartley-Brown, Clifton C Mo, et al.Oncotarget|November 9, 2017
HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancerTeru Hideshima, Ralph Mazitschek, Jun Qi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myelomaConstantine S Mitsiades, Faith E Davies, Jacob P Laubach, et al.Immunological Reviews|December 17, 2014
Targeting the bone marrow microenvironment in multiple myelomaYawara Kawano, Michele Moschetta, Salomon Manier, et al.Oncotarget|August 26, 2021
Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancerTeru Hideshima, Ralph Mazitschek, Jun Qi, et al.Blood|May 14, 2010
Kidney disease associated with plasma cell dyscrasiasEliot C Heher, Nelson B Goes, Thomas R Spitzer, et al.Pageof 83